Perispinal administration of anti-TNF agent results in rapid cognitive improvement in AD
This article has no abstract so we have provided the first paragraph of the full text.
A substantial amount of evidence indicates that excess tumor necrosis factor (TNF) has a key role in the pathogenesis of Alzheimer's disease (AD). A pilot study demonstrated that perispinal extrathecal administration of the potent anti-TNF therapeutic etanercept (approved for the treatment of rheumatoid arthritis in 1998) conferred sustained cognitive improvements in patients with AD. During the course of the pilot trial, the researchers noted rapid clinical improvement in the patients following etanercept administration. As the original trial protocol did not allow for the measurement of improvements at short intervals, the authors have now quantitatively documented the rapid cognitive improvements seen in a new patient with late-onset AD following perispinal etanercept administration.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.